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Chagas disease (CD), a neglected tropical disease caused by Trypanosoma cruzi, remains a serious public health problem in sev-
eral Latin American countries. The available chemotherapies for CD have limited efficacy and exhibit undesirable side effects.
Aromatic diamidines and arylimidamides (AIAs) have shown broad-spectrum activity against intracellular parasites, including
T. cruzi. Therefore, our aim was to evaluate the biological activity of eight novel AIAs (16DAP002, 16SAB079, 18SAB075,
23SMB022, 23SMB026, 23SMB054, 26SMB070, and 27SMB009) against experimental models of T. cruzi infection in vitro and in
vivo. Our data show that none of the compounds induced a loss of cellular viability up to 32 M. Two AIAs, 18SAB075 and
16DAP002, exhibited good in vitro activity against different parasite strains (Y and Tulahuen) and against the two relevant
forms of the parasite for mammalian hosts. Due to the excellent selective indexes of 18SAB075, this AIA was moved to in vivo
tests for acute toxicity and parasite efficacy; nontoxic doses (no-observed-adverse-effect level [NOAEL], 50 mg/kg) were em-
ployed in the tests for parasite efficacy. In experimental models of acute T. cruzi infection, 18SAB075 reduced parasitemia levels
only up to 50% and led to 40% protection against mortality (at 5 mg/kg of body weight), being less effective than the reference
drug, benznidazole.
Chagas disease (CD) is a neglected tropical disease caused by theintracellular flagellate protozoan Trypanosoma cruzi, which
presents a complex life cycle with distinct morphological stages in
its obligatory passage through vertebrate and invertebrate hosts
(1). Currently, there are approximately 10 million infected indi-
viduals in areas of Latin America where CD is endemic, and many
reports also point to the occurrence of CD in geographical areas
where it is not endemic, such as the United States and Europe,
mainly attributed to migration of infected people (2–6). CD can
be transmitted by Triatominae insect feces, blood transfusion, or-
gan transplantation, and laboratory accidents and through oral
and congenital routes (7, 8). This pathology has two successive
phases, a short, acute phase characterized by a patent parasitemia,
followed by a chronic phase in which most of the infected individ-
uals remain asymptomatic (indeterminate form), but about one-
third may later manifest cardiac and/or digestive complications,
developed progressively for years or decades after infection (9,
10). Benznidazole (Bz) and nifurtimox, introduced into clinical
therapy about 40 years ago, are the only available drugs. Both have
several shortcomings related to their required long periods of
treatment, high toxicity, variable results, and low efficacy during
the chronic phase, justifying the identification of novel therapies
(11–13). Aromatic diamidines and analogues exhibit broad-spec-
trum activity against pathogenic microorganisms, including T.
cruzi (14). Among the different tested derivatives of amidine com-
pounds, the most effective against T. cruzi have been the bis-
arylimidamides (AIAs) like DB766 (15) and DB1831 (16). Thus,
in this study, we assayed the biological activities of eight novel
AIAs (16DAP002, 16SAB079, 18SAB075, 23SMB022, 23SMB026,
23SMB054, 26SMB070, and 27SMB009) against experimental
models of T. cruzi infection in vitro and in vivo, using different
parasite strains, and also explored their toxicities in cardiac cell
cultures and mouse models of acute toxicity.
MATERIALS AND METHODS
Synthesis of the arylimidamides. The eight arylimidamides, all isolated
as their hydrochloride salts, were prepared by three general methods (see
the supplemental material). Briefly, phenylimidamides 16DAP022 and
16SAB079 (Fig. 1) were prepared by the reaction of 2,7-diaminocarbazole
(prepared by reduction of 2,7-dinitroocarbazole) (17) or m-xylylenedi-
amine with (2-naphthyl)methyl benzothioimidate hydrobromide (18).
The 2-pyridylimidamide 18SAB075 (Fig. 2) was prepared by the reaction
of 4,4=-diaminodiphenylacetylene (19, 20) with 2-cyanopyridine by the
method of Lange et al. (21) but using lithium (rather than sodium) bis
(trimethylsilyl)amide. The reaction of the methyl imidate derivatives of 2-
or 4-cyanopyridine with the appropriate ,-diamines or spermidine
gave 2-pyridylimidamides 23SMB022, 23SMB026, and 23SMB054 and
4-pyridylimidamides 26SBM070 and 27SMB009 (Fig. 3).
Mammalian cell cultures. For the in vitro analysis of compound tox-
icity and effects against intracellular parasites (Y strain), primary cultures
of embryonic cardiomyocytes (CM) were obtained from Swiss mice as
previously reported (22). After purification, the CM were seeded at a
density of 0.2  106 and 0.05  106 cells/well, respectively, in 24- and
96-well microplates containing gelatin-coated coverslips. The cultures
were then maintained at 37°C in Dulbecco’s modified medium supple-
mented with 10% horse serum, 5% fetal bovine serum, 2.5 mM CaCl2, 1
mM L-glutamine, and 2% chicken embryo extract (DMEM). For the fur-
ther analysis of the effect on intracellular parasites of the Tulahuen strain
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(parasites expressing the Escherichia coli -galactosidase gene), monolay-
ers of mouse L929 fibroblasts were cultivated (4  103 cells/well in 96-well
microplates) at 37°C in RPMI 1640 medium (pH 7.2 to 7.4) without
phenol red (Gibco BRL) supplemented with 10% fetal bovine serum
(FBS) and 2 mM glutamine (RPMIS), as reported previously (23).
Parasites. Bloodstream trypomastigote (BT) forms of the Y strain
were obtained from the blood samples of infected albino Swiss mice at the
peak of parasitemia. The purified parasites were resuspended in Eagle’s
medium modified by Dulbecco’s medium (DME) supplemented with
10% FBS (DMES) as reported previously (22). The effect on the intracel-
lular forms was investigated by both the infection of L929 cell lineages
with tissue culture-derived trypomastigotes (Tulahuen strain expressing
the E. coli -galactosidase gene) and the infection of CM with blood-
stream trypomastigotes (Y strain) using a 10:1 ratio, following previously
established protocols (15, 23). Stock solutions were prepared in dimethyl
sulfoxide (DMSO) with the final concentrations of the solvent never ex-
ceeding 0.6% and 10% for in vitro and in vivo analysis, respectively,
which did not exert any toxicity (data not shown). Benznidazole (Bz)
(2-nitroimidazole; Laboratório Farmacêutico do Estado de Pernambuco
[LAFEPE], Brazil) was used as a reference drug.
Cytotoxicity in vitro tests. CM were incubated for 24 h at 37°C with
different concentrations of each compound (up to 96 M) diluted in
DMEM (without phenol red), their morphology and spontaneous con-
tractibility were evaluated by light microscopy, and then their cellular
viability was determined by the alamarBlue assay. For this colorimetric
bioassay, 10 l alamarBlue (Invitrogen) was added to each well, and the
plate was further incubated for 24 h, after which the absorbances at 570
and 600 nm were measured. As negative controls, alamarBlue assays were
also performed in the absence of cells, using only DMEM and DMEM
containing each tested compound (at 96 M). The results are expressed as
the percent differences in the decreases between compound-treated and
vehicle-treated cells by following the manufacturer’s instructions and the
EC50 value corresponds to the concentration that reduces the cellular
viability by 50% (23).
Trypanocidal analysis. Bloodstream trypomastigotes of the Y strain
(5  106/ml) were incubated for 24 h at 37°C in RPMI medium in the
presence or absence of serial dilutions of the compounds (0 to 32 M).
After compound incubation, the parasite death rates were determined by
light microscopy through direct quantification of the numbers of live
parasites using a Neubauer chamber, and the EC50 (compound concen-
tration that reduces 50% of the number of parasites) was then calculated.
For the assays on intracellular forms, different protocols were per-
formed with the Y and Tulahuen strains. For Tulahuen-infected L929
cells, the cultures were exposed to 1.0 g/ml diluted in RPMIS, and those
compounds that presented 50% reductions in the parasite infection
index were further screened using increasing concentrations with the aim
of determining the EC50s (23). After 96 h of compound incubation at
37°C, chlorophenol red glycoside (500 M) in 0.5% Nonidet P40 was
added to each well, and the plate was incubated for 18 h at 37°C. Next, the
absorbance was measured at 570 nm. Uninfected and infected cultures
submitted to vehicle and Bz exposure were tested in parallel. The results
are expressed as the percentage of T. cruzi growth inhibition in com-
pound-tested cells compared to that in the infected cells and untreated
cells (23).
For the analysis of the effect against intracellular amastigotes from the
Y strain, after 24 h of parasite-host cell interaction, the infected cultures
were washed to remove free parasites and then incubated for another 48 h
with increasing concentrations of the test compounds. CM were main-
tained at 37°C in an atmosphere of 5% CO2 and air, and the medium was
replaced every 24 h. Then, untreated and treated infected CM were fixed
and stained with Giemsa solution, and the mean numbers of infected host
cells and of parasites per infected cell were scored as reported previously
(16). Only characteristic T. cruzi nuclei and kinetoplasts were counted as
surviving parasites since irregular structures might mean parasites under-
going death. The compound activity was estimated by calculating the
infection index (II) (the percentage of infected cells times the average
number of intracellular amastigotes per infected host cell) (24). Triplicate
assays were run on the same plate, and at least two assays were performed
in each analysis.
Mouse acute toxicity. In order to determine the no-observed-ad-
verse-effect level (NOAEL), each dose of the tested compounds (12.5 to
200 mg/kg of body weight) was injected by the intraperitoneal (i.p.) route
individually in Swiss Webster female mice (20 to 23 g). On days 2 and 3,
mice were inspected for toxic and subtoxic symptoms according to the
Organization for Economic Co-operation and Development (OECD)
guidelines. Forty-eight hours after compound injection, the NOAEL val-
ues were determined, and plasma biochemical analysis was performed for
alanine aminotransferase (ALT), urea, and creatine kinase (CK) as re-
ported previously (16).
Mouse infection and treatment schemes. Male Swiss mice were ob-
tained from the Fundação Oswaldo Cruz (FIOCRUZ) animal facilities
(Rio de Janeiro, Brazil). Mice were housed at a maximum of 6 per cage and
kept in a conventional room at 20 to 24°C under a 12 h/12 h light/dark
cycle. The animals were provided with sterilized water and chow ad libi-
tum. Infection was performed by i.p. injection of 104 bloodstream trypo-
mastigotes (Y strain). The animals (18 to 21 g) were divided into the
following groups: uninfected (noninfected and untreated), untreated (in-
fected with T. cruzi but treated only with vehicle), and treated (infected
and treated i.p. with 0.5 to 20 mg/kg/day test compound [up to 0.2 ml] or
with 100 mg/kg/day Bz orally [p.o.]). The mouse treatment started at 5
days postinfection (dpi) followed by (i) a 1-s dose at 8 dpi or (ii) five
consecutive daily doses. For Bz treatment, infected mice received a 0.2-ml
oral dose (gavage) following the same therapeutic schemes as described
above (15).
Parasitemia, mortality rates, and ponderal curve analysis. Para-
sitemia was individually checked by direct microscopic counting of para-
sites in 5 l of blood, as described before (25). Body weight was evaluated
weekly, and mortality was checked daily until 30 days posttreatment and
expressed as a percentage of cumulative mortality (%CM) (15).
Ethics. All procedures were carried out in accordance with the guide-
lines established by the FIOCRUZ Committee of Ethics for the Use of
Animals (CEUA LW-16/2013).
RESULTS
The screening of the eight novel arylimidamides (Fig. 1 to 3)
against bloodstream trypomastigotes (Y strain) revealed that after
2 h of incubation at 37°C, 18SAB075 and 16DAP002 showed con-
siderable activity, displaying EC50s of 11 and 14 M (Table 1).
FIG 1 Synthesis of 16DAP002 and 16SAB079. Reagents and conditions: (a)
appropriate diamine, ethanol (plus acetonitrile for 16DAP022), 0 to 25°C,
overnight (66 to 71%).
FIG 2 Synthesis of 18SAB075. Reagents and conditions: (a) 2-cyanopyridine,
lithium bis(trimethylsilyl)amide, tetrahydrofuran, 25°C, 2 days, (16%).
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After 24 h of incubation, both were more effective than Bz, dis-
playing EC50s of 0.3 and 3 M, respectively, with the former mol-
ecule exhibiting about 43-fold higher trypanocidal effect than the
reference drug Bz (Table 1). In vitro analysis of cytotoxicity on
cardiac cell cultures performed by the alamarBlue assay showed
that up to 32 M, none of the studied compounds caused loss of
cellular viability (Table 1). An alamarBlue assay performed in the
absence of cells, with DMEM containing or not containing each
tested compound (at 96 M), showed no alterations in the absor-
bance measurements (data not shown). When tested on T. cruzi-
infected host cells (the Tulahuen strain transfected with a -galac-
tosidase gene) under a standardized screening protocol using a
fixed concentration of 1 g/ml (23), again both 16DAP002 and
18SAB075 were effective (Table 2). Next, the two AIAs were
screened against Tulahuen-infected host cells in order to deter-
mine the EC50s. The findings showed that 18SAB075 was the most
active with values of 1.5 M after 96 h of incubation, comparable
to those for Bz and 16DAP002 (Table 3). Further analysis of the
effect of 18SAB075 against T. cruzi-infected cardiac cells using
another strain (Y strain) confirmed the promising activity
(EC50  0.9 M) of this AIA, which was especially notable in the
data for the mean number of infected cardiac cells when the in-
fected cultures were incubated with concentrations up to 32 M
without causing loss of host cell viability (Fig. 4A and B). Although
no loss of viability was noted up to 32 M as seen by the alamar-
Blue method, light microscopy analysis demonstrated that
16SAB002 at concentrations 3.5 M induced cellular vacuoliza-
tion and impaired the contractibility of the cardiac cells in vitro.
Also, no effect on the levels of T. cruzi infection was observed when
nontoxic doses (3.5 M) of this AIA were tested (data not
shown).
Next, due to the higher selectivity indexes of 18SAB075 on
bloodstream trypomastigotes (106; Table 1) and on intracel-
lular forms (40; Fig. 4), this compound was moved to in vivo
analysis.
Our first in vivo step was to evaluate aspects of the acute toxicity
of 18SAB075, aiming to determine its NOAEL value. The admin-
istration of this AIA via the i.p. route to Swiss female mice (12.5 to
200 mg/kg) followed for 48 h showed that none of the doses caused
FIG 3 Synthesis of 23SMB022, 23SMB026, 23SMB054, 26SMB070, and 27SMB009. Reagents and conditions: (a) sodium methoxide, methanol, 25°C, 1 week;
(b) appropriate ,-diamine (or spermidine for 23SMB054), 4 M HCl in dioxane, methanol, 25°C (5 to 92%).
TABLE 2 Activity of arylimidamides (at 1 g/ml) against intracellular
forms of T. cruzi (Tulahuen strain transfected with -galactosidase)
after treatment for 96 h at 37°C
Compound
Inhibition of the host
cell infection
(mean 	 SD) (%)
16DAP002 58 	 31
18SAB075 50 	 7
26SMB070 15 	 8
16SAB079 4 	 5
23SMB054 3 	 4
23SMB022 1 	 1
27SMB009 0 	 0
23SMB026 0 	 0
Benznidazole 82 	 3
TABLE 1 Trypanocidal activity (EC50) of the studied arylimidamides
against bloodstream trypomastigotes of T. cruzi (Y strain) and their
selectivity index related to cardiomyocytes (EC50)
Compound




(24 h)2 h 24 h
18SAB075 11 	 1 0.3 	 0 32 106
16DAP002 14 	 3 3 	 1 32 11
27SMB009 100 85 	 21 32 0.4
23SMB054 100 100 32
23SMB022 100 100 32
23SMB026 100 100 32
26SMB070 100 100 32
16SAB079 100 100 32
Benznidazole 100 13 	 2b 1,000 77
a Treatment for 24 h at 37°C. Selectivity index (SI)  EC50 for cardiomyocytes/EC50 for
parasites.
b Value from da Silva et al. (16).
Timm et al.
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death. Up to 50 mg/kg, no alteration in animal behavior (com-
pared to that of vehicle-treated mice) was found. However, in-
creased doses induced visible neurological disorders like tremors,
ataxia, and hyperactivity (data not shown). The gross pathological
examination performed at 48 h after drug administration showed
that 200 mg/kg induced hemorrhagic hepatic signs (data not
shown). This hepatic injury was confirmed by the biochemical
plasma analysis of the higher dose as increased levels of aspartate
transaminase (AST) and ALT were found compared to those for
the animals from the other groups (data not shown). Then, the
efficacy of 18SAB075 was tested in Swiss male mice inoculated
with 104 bloodstream parasites using a therapeutic scheme em-
ploying doses administered once a day, at 5 and 8 dpi (Fig. 5) that
correspond to the onset and parasitemia peaks, respectively, in
this animal model (15). Only parasitemia-positive mice were
used, and Bz treatment was run in parallel using standard protocol
(100 mg/kg p.o.), following the same therapeutic scheme as de-
scribed above (Fig. 5). Although 20 and 10 mg/kg did not reduce
or only slightly impaired (20%), respectively, the parasitemia lev-
els, the lower dose (5 mg/kg) resulted in a 50% decrease in the
parasitism peak decrease, also leading to 40% animal survival
while all the other mice (except for the Bz group) died (Fig. 5).
Then, aiming to allow a longer plasma exposure of the com-
pound but taking into consideration the use of maximum non-
toxic doses (up to 50 mg/kg), we performed additional studies,
providing the AIA for 5 daily consecutive days, starting at 5 dpi
(Fig. 6). As expected for this experimental mouse model of T. cruzi
acute infection, infected and vehicle-treated animals presented
high parasitemia and no animal survival (Fig. 5 and 6). When
18SAB075 was administered via the i.p. route, none of the doses
reduced the parasitemia or protected against mortality. As ex-
pected, Bz completely suppressed the parasitemia and conferred
100% survival (Fig. 6). Also, none of the doses were able to protect
the animals against the body weight loss (data not shown) induced
by the T. cruzi infection in this experimental acute model (26).
DISCUSSION
Structural variations in the presently available AIAs include
seven different linkers between the two AIA moieties and three
different outer aromatic rings. Those molecules containing
multiple or fused aromatic rings in their linkers were active
against the bloodstream and intracellular parasites. The most
active compound, 18SAB075, contains a diphenylacetylene
linker, which offers extended conjugation. The second most
active compound, 16DAP002, contains a carbazole system as
its linker, which also offers extended conjugation but a more
rigid conformation due to the fused rings. Both compounds
displayed AIA nitrogen atoms attached directly to aromatic
rings. The xylene derivative 26SMB070, which was less active,
bears an aromatic ring in its linker, but the nitrogen atoms are
attached to aliphatic carbons. Analogues of the two most active
compounds containing the same linkers but different outer
rings were not included in this study.
TABLE 3 In vitro effect (EC50s) of arylimidamides against intracellular
forms of T. cruzi (Tulahuen strain transfected with -galactosidase)
after treatment for 96 h at 37°C
Compound EC50 (mean 	 SD) (M)
16DAP002 4.1 	 1.8
18SAB075 1.5 	 0.2
Benznidazole 2.6 	 0.8
FIG 4 Activity (EC50s) and selective index (SI) of 18SAB075 against intracellular forms of T. cruzi (Y strain) after treatment for 48 h at 37°C. (A) T. cruzi-infected
cardiac cells incubated with vehicle. (B) T. cruzi-infected cardiac cells incubated with 32 M 18SAB075. The arrows point to intracellular parasites. Infection
index, host cell infection  number of parasites/infected host cell, as reported in Batista et al. (15).
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Chemotherapeutic options for treating chagasic patients cur-
rently depend on only two nitro derivative drugs, namely, ben-
znidazole (2-nitroimidazole; Laboratório Farmacêutico do Es-
tado de Pernambuco [LAFEPE], Brazil) and nifurtimox (5-
nitrofuran, Bayer 2502; Bayer, Germany) (27). Both cause severe
side effects, resulting in discontinuation of the treatment and low
effectiveness, especially in the later chronic phase of the disease,
demanding the identification of novel drugs to treat this devastat-
ing chronic pathology. However, there is a lack of interest from
most pharmaceutical companies for discovery of new anti-T. cruzi
agents mainly due to the long time and high costs associated with
the drug pipeline for this and other neglected parasitic illnesses
that afflict millions of the poorest people worldwide (28). In this
context, our aim was to explore the possibility of finding new
amidine derivatives with considerable activity against T. cruzi in
vitro and in vivo which possess the potential to act as clinical can-
didates against this neglected parasitic disease. In this vein, eight
novel AIAs were screened against the bloodstream and intracellu-
lar forms of the parasite and two of them, 18SAB075 and
16DAP002, demonstrated higher activity, with EC50s of 
4 M.
The two compounds were effective against different strains (Y and
Tulahuen), and due to its high selectivity, 18SAB075 was further
examined in in vivo analyses for preliminary ascertainment of
acute toxicities and for efficacy determination using an acute
mouse model of T. cruzi infection (male Swiss mice infected with
Y strain). The follow-up of acute toxicity signs for 48 h after
18SAB075 administration via the i.p. route showed that although
at up to 50 mg/kg, no alterations were noticed, considerable toxic
side effects like ataxia, hyperactivity, and tremors were found with
doses of 100 and 200 mg/kg. The gross pathological examination
confirmed that the higher dose also induced hemorrhagic hepatic
signs that were corroborated by increased plasma levels of hepatic
markers like AST. Thus, efficacy analysis was further explored
using only doses 20 mg/kg/day and never exceeding cumulative
doses of 50 mg/kg. Bz was included as a reference drug, given at its
effective dose of 100 mg/kg/day (23). The i.p. administration of
FIG 5 In vivo effect of 18SAB075 on T. cruzi infection using male Swiss mice inoculated with 104 bloodstream trypomastigotes (Y strain). The activities of 5, 10,
and 20 mg/kg/day 18SAB075 (i.p.) and of benznidazole (100 mg/kg/day by gavage) given at 5 and 8 dpi was evaluated through parasitemia levels (top) and
cumulative mortality (bottom).
Timm et al.
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18SAB075 in all assayed therapeutic schemes (2 and 5 days of
treatment) using nontoxic doses failed to demonstrate the activity
of this diphenylacetylene AIA in vivo, while Bz not only suppressed
the parasitemia but also induced 100% protection against mortal-
ity due to the experimental infection as described previously (26).
Previous data using bis-AIAs like 2,5-bis[2-(2-propoxy)-4-(2-
pyridylimino)aminophenyl]furan (DB 766) (15) and a related an-
alog (DB 1831) (16) showed their high activity in vivo in the acute
experimental mouse models of T. cruzi, exhibiting trypanocidal
effects similar to that of Bz. In fact, with the same highly stringent
experimental in vivo model as presently used for 18SAB075, the
two previous studies reported that the presence of pyrimidine and
pyridine units of bis-AIAs seemed to be advantageous for T. cruzi
activity (14), supporting the continuity of preclinical studies of
novel related molecules with the aim of finding new alternatives
for treating Chagas disease.
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